<DOC>
	<DOCNO>NCT01061970</DOCNO>
	<brief_summary>The objective study ass compare preliminary efficacy , safety tolerability fispemifene 300 mg placebo give daily 4 week treatment hypogonadal men chronic obstructive pulmonary disease ( COPD ) oral glucocorticoid therapy .</brief_summary>
	<brief_title>Efficacy Safety Fispemifene Treatment Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are Oral Glucocorticoid Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . The subject sign write informed consent participate study agree follow dosing instruction complete require study visit . 2 . The subject COPD define postbronchodilator FEV1/FVC &lt; 0.7 measured screening . 3 . The subject stable dose oral glucocorticoid ( dose change past 3 month anticipate change subject 's participation study ) 4 . The subject male ≥20 year age time randomization . 5 . The subject screen total testosterone level confirmatory baseline total testosterone level ≤ 350 ng/dl . Testosterone level determine early morning ( 0700h 0900h ) specimen . 6 . The subject serum LH level 1.715.0 IU/L FSH level 1.515.0 IU/L screen visit . 1 . Subject elevate prolactin . ( ≥21.5 ng/mL upper limit reference lab range ) 2 . Subject evidence Benign Prostatic Hypertrophy ( BPH ) obstructive symptom indicate International Prostate Symptom Score ( IPSS ) ≥15 . 3 . Subject history current breast cancer , prostate cancer , abnormal DRE ( suspicion malignancy ) elevate PSA ( &gt; 4 ng/ml ) malignancy . History basal cell carcinoma allow . 4 . Subject clinically significant endocrine metabolic disease ( e.g . thyroid disease , type I diabetes , severe hyperlipidemia ) . Severe hyperlipidemia define total cholesterol &gt; 300 mg/dL triglyceride &gt; 400 mg/dL . Type II diabetes allow HbAlc level le 8 % . 5 . Subject clinically significant cardiovascular disease , abnormal finding baseline ECG , related COPD . 6 . Subject systolic blood pressure ≥150 mmHg diastolic blood pressure ≥85 mmHg . 7 . Subject significant polycythemia . ( Hemoglobin &gt; 17.5 gm/dL upper limit reference lab range ) 8 . Subject current history severe renal hepatic impairment . 9 . Subject current history thromboembolic blood coagulation disorder . 10 . Subject current history cerebrovascular incident ( e.g . bleeding , stroke transient ischemic attack ) . 11 . Subject clinically relevant abnormal finding safety laboratory test include liver enzyme ( ALT , AST ) 1.5 time upper limit normal test laboratory creatinine &gt; 1.4 mg/dl . 12 . Subject heterozygous homozygous Factor V Leiden . 13 . Subject clinically significant abnormal finding physical examination relate COPD . 14 . Subject use transdermal testosterone therapy within 14 day intramuscular testosterone therapy within 30 day prior screen blood draw . 15 . Subject use form hormone therapy affect estrogen and/or androgen metabolism within 30 day prior screen blood draw . 16 . Subject use injectable hormonal therapy ( e.g . luteinizing hormone release hormone ( LHRH ) antagonist agonist , growth hormone ( GH ) therapy ) within 30 day prior screen blood draw . 17 . Subject used medication affect HypothalamicPituitaryGonadal ( HPG ) axis within 30 day prior screen blood draw . 18 . Subject use dietary supplement and/or herbal therapy affect estrogen and/or testosterone metabolism HPG axis within 30 day prior screen blood draw . 19 . Subject use potent inhibitor CYP3A4 ( e.g . ketoconazole , ritonavir , etc ) Day 1 intend use medication study . 20 . Subject use potent inducer CYP3A4 Randomization Day 1or intend use medication study . 21 . Subject use medication metabolize CYP2B6 , CYP2C9 , CYP2C19 CYP3A4 narrow therapeutic index Day 1 intend use medication study 22 . Subject consume 14 drink contain alcohol per week . ( One drink = 1.5 oz . distilled spirit , 12 oz . beer , 5 oz . wine. ) . 23 . Subject history current drug abuse within 6 month prior screen visit . 24 . Subject currently untreated sleep apnea . 25 . Subject participant another clinical intervention study within 30 day prior planned randomization Day 1 . 26 . Subject physical mental condition , opinion investigator may interfere subject 's ability comply study procedure . 27 . Subject previously participate study clinical study fispemifene .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>